First Time Loading...

Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 47.15 EUR 1.4%
Updated: May 15, 2024

Intrinsic Value

Pharmanutra SpA develops nutraceutical products and medical devices. [ Read More ]

The intrinsic value of one PHN stock under the Base Case scenario is 38.53 EUR. Compared to the current market price of 47.15 EUR, Pharmanutra SpA is Overvalued by 18%.

Key Points:
PHN Intrinsic Value
Base Case
38.53 EUR
Overvaluation 18%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Pharmanutra SpA

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling PHN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Pharmanutra SpA

Provide an overview of the primary business activities
of Pharmanutra SpA.

What unique competitive advantages
does Pharmanutra SpA hold over its rivals?

What risks and challenges
does Pharmanutra SpA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Pharmanutra SpA.

Provide P/S
for Pharmanutra SpA.

Provide P/E
for Pharmanutra SpA.

Provide P/OCF
for Pharmanutra SpA.

Provide P/FCFE
for Pharmanutra SpA.

Provide P/B
for Pharmanutra SpA.

Provide EV/S
for Pharmanutra SpA.

Provide EV/GP
for Pharmanutra SpA.

Provide EV/EBITDA
for Pharmanutra SpA.

Provide EV/EBIT
for Pharmanutra SpA.

Provide EV/OCF
for Pharmanutra SpA.

Provide EV/FCFF
for Pharmanutra SpA.

Provide EV/IC
for Pharmanutra SpA.

Show me price targets
for Pharmanutra SpA made by professional analysts.

What are the Revenue projections
for Pharmanutra SpA?

How accurate were the past Revenue estimates
for Pharmanutra SpA?

What are the Net Income projections
for Pharmanutra SpA?

How accurate were the past Net Income estimates
for Pharmanutra SpA?

What are the EPS projections
for Pharmanutra SpA?

How accurate were the past EPS estimates
for Pharmanutra SpA?

What are the EBIT projections
for Pharmanutra SpA?

How accurate were the past EBIT estimates
for Pharmanutra SpA?

Compare the revenue forecasts
for Pharmanutra SpA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pharmanutra SpA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pharmanutra SpA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pharmanutra SpA compared to its peers.

Compare the P/E ratios
of Pharmanutra SpA against its peers.

Discuss the investment returns and shareholder value creation
comparing Pharmanutra SpA with its peers.

Analyze the financial leverage
of Pharmanutra SpA compared to its main competitors.

Show all profitability ratios
for Pharmanutra SpA.

Provide ROE
for Pharmanutra SpA.

Provide ROA
for Pharmanutra SpA.

Provide ROIC
for Pharmanutra SpA.

Provide ROCE
for Pharmanutra SpA.

Provide Gross Margin
for Pharmanutra SpA.

Provide Operating Margin
for Pharmanutra SpA.

Provide Net Margin
for Pharmanutra SpA.

Provide FCF Margin
for Pharmanutra SpA.

Show all solvency ratios
for Pharmanutra SpA.

Provide D/E Ratio
for Pharmanutra SpA.

Provide D/A Ratio
for Pharmanutra SpA.

Provide Interest Coverage Ratio
for Pharmanutra SpA.

Provide Altman Z-Score Ratio
for Pharmanutra SpA.

Provide Quick Ratio
for Pharmanutra SpA.

Provide Current Ratio
for Pharmanutra SpA.

Provide Cash Ratio
for Pharmanutra SpA.

What is the historical Revenue growth
over the last 5 years for Pharmanutra SpA?

What is the historical Net Income growth
over the last 5 years for Pharmanutra SpA?

What is the current Free Cash Flow
of Pharmanutra SpA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pharmanutra SpA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pharmanutra SpA

Current Assets 58.7m
Cash & Short-Term Investments 6.2m
Receivables 22.7m
Other Current Assets 29.7m
Non-Current Assets 53.8m
Long-Term Investments 297k
PP&E 26.4m
Intangibles 22.5m
Other Non-Current Assets 4.6m
Current Liabilities 27.6m
Accounts Payable 13.7m
Accrued Liabilities 3.4m
Short-Term Debt 627k
Other Current Liabilities 10m
Non-Current Liabilities 30.4m
Long-Term Debt 23.4m
Other Non-Current Liabilities 7m
Efficiency

Earnings Waterfall
Pharmanutra SpA

Revenue
100.2m EUR
Cost of Revenue
-2.4m EUR
Gross Profit
97.8m EUR
Operating Expenses
-74.4m EUR
Operating Income
23.4m EUR
Other Expenses
-10.6m EUR
Net Income
12.8m EUR

Free Cash Flow Analysis
Pharmanutra SpA

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

PHN Profitability Score
Profitability Due Diligence

Pharmanutra SpA's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional 3-Years Revenue Growth
71/100
Profitability
Score

Pharmanutra SpA's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

PHN Solvency Score
Solvency Due Diligence

Pharmanutra SpA's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Short-Term Solvency
Long-Term Solvency
65/100
Solvency
Score

Pharmanutra SpA's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHN Price Targets Summary
Pharmanutra SpA

Wall Street analysts forecast PHN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHN is 82.28 EUR with a low forecast of 77.77 EUR and a high forecast of 90.3 EUR.

Lowest
Price Target
77.77 EUR
65% Upside
Average
Price Target
82.28 EUR
75% Upside
Highest
Price Target
90.3 EUR
92% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

PHN Price
Pharmanutra SpA

1M 1M
-12%
6M 6M
-9%
1Y 1Y
-17%
3Y 3Y
+32%
5Y 5Y
+199%
10Y 10Y
+270%
Annual Price Range
47.15
52w Low
45.4
52w High
63.1
Price Metrics
Average Annual Return 47.35%
Standard Deviation of Annual Returns 47.72%
Max Drawdown -41%
Shares Statistics
Market Capitalization 453.3m EUR
Shares Outstanding 9 681 000
Percentage of Shares Shorted
N/A

PHN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Pharmanutra SpA Logo
Pharmanutra SpA

Country

Italy

Industry

Consumer products

Market Cap

453.3m EUR

Dividend Yield

1.66%

Description

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

Contact

PISA
Pisa
Via delle Lenze n. 216/B
+390507846500
https://www.pharmanutra.it/

IPO

2017-07-18

Employees

65

Officers

Chairman & President
Mr. Andrea Lacorte
Vice Chairman, MD & VP
Mr. Roberto Lacorte
Delegate Advisor, COO & Executive Director
Mr. Carlo Volpi
Scientific Director & Executive Director
Mr. Germano Tarantino

See Also

Discover More
What is the Intrinsic Value of one PHN stock?

The intrinsic value of one PHN stock under the Base Case scenario is 38.53 EUR.

Is PHN stock undervalued or overvalued?

Compared to the current market price of 47.15 EUR, Pharmanutra SpA is Overvalued by 18%.